» Articles » PMID: 12725421

Sulfotransferase 1A1 (SULT1A1) Polymorphism, PAH-DNA Adduct Levels in Breast Tissue and Breast Cancer Risk in a Case-control Study

Overview
Specialty Oncology
Date 2003 May 3
PMID 12725421
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Gene-environment interactions are hypothesized to be major contributors to susceptibility to environmental carcinogens and interindividual variability in cancer risk. We present findings on associations between genetic susceptibility due to inherited polymorphisms of the Phase II detoxification enzyme sulfotransferase 1A1 (SULT1A1), breast cancer risk, and polycyclic aromatic hydrocarbon (PAH)-DNA adducts. A hospital based case-control study was conducted at the New York-Presbyterian Medical Center (NYPMC). The study utilized two control groups: one comprised of women with benign breast disease (BBD) and the other comprised of women visiting NYPMC for routine gynecologic checkups (healthy controls). Blood samples were collected from cases and controls; and breast tissue from pathology blocks was collected from cases (tumor and non-tumor tissue) and BBD controls (benign tissue). PAH-DNA adduct levels were measured by immunohistochemistry in breast tissue samples, and the SULT1A1 (Arg/His) polymorphism at codon 213 was determined by PCR RFLP analyses using DNA from white blood cells. Increasing number of His alleles was modestly associated with breast cancer case-control status, when cases were compared to healthy controls (p for trend = 0.08), when cases were compared to BBD controls (p for trend = 0.08) and when cases were compared to both control groups combined (p for trend = 0.07). Contrary to our hypothesis PAH-DNA adduct levels in breast tissue were not associated with SULT1A1 genotype. Our findings are consistent with a prior report that the Arg/His polymorphism in SULT1A1 is associated with breast cancer risk.

Citing Articles

Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.

Hakkaart C, Pearson J, Marquart L, Dennis J, Wiggins G, Barnes D Commun Biol. 2022; 5(1):1061.

PMID: 36203093 PMC: 9537519. DOI: 10.1038/s42003-022-03978-6.


SULT genetic polymorphisms: physiological, pharmacological and clinical implications.

Kurogi K, Rasool M, Alherz F, El Daibani A, Bairam A, Abunnaja M Expert Opin Drug Metab Toxicol. 2021; 17(7):767-784.

PMID: 34107842 PMC: 8369464. DOI: 10.1080/17425255.2021.1940952.


Relationship of SULT1A1 copy number variation with estrogen metabolism and human health.

Liu J, Zhao R, Ye Z, Frey A, Schriver E, Snyder N J Steroid Biochem Mol Biol. 2017; 174:169-175.

PMID: 28867356 PMC: 5675753. DOI: 10.1016/j.jsbmb.2017.08.017.


Cytosolic sulfotransferase 1A1 regulates HIV-1 minus-strand DNA elongation in primary human monocyte-derived macrophages.

Swann J, Murry J, Young J Virol J. 2016; 13:30.

PMID: 26906565 PMC: 4765207. DOI: 10.1186/s12985-016-0491-9.


Sulfotransferase SULT1A1 Arg213His polymorphism with cancer risk: a meta-analysis of 53 case-control studies.

Xiao J, Zheng Y, Zhou Y, Zhang P, Wang J, Shen F PLoS One. 2014; 9(9):e106774.

PMID: 25225888 PMC: 4165769. DOI: 10.1371/journal.pone.0106774.